Abstract: Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a removable soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum chamber. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing penile and cavernosal tumescence by application of a vacuum are also provided.

Abstract: Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum device. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing clitoral and cavernosal tumescence by application of a vacuum are also provided.

Abstract: Various systems, processes, tools and techniques are provided for managing and processing alerts associated with different business events that impact a corporate entity. In various aspects, the system may employ an event-driven architecture to process business events and then provide customers and other system users with a mechanism for having have visibility into those business events through a subscription process, for example. Subscribers may be offered the ability to tap into different streams of business events, filter the event streams to obtain information only for events of interest, and then receive alerts associated with the events via one or more communication media or channels.

Abstract: Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum device. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing clitoral and cavernosal tumescence by application of a vacuum are also provided.

Abstract: Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a removable soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum chamber. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing penile and cavernosal tumescence by application of a vacuum are also provided.

Abstract: A method of inducing hemostasis in a wound. A hemostatic product is applied to a wound. The hemostatic product includes at least one hemostasis component. The hemostatic product is retained with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product. At least a portion of the hemostatic product is dissolved. Hemostasis is induced in the wound with the at least one hemostasis component. The hydrogel material is separated from the wound. Substantially all of the hemostatic product remains on the wound.

Abstract: A method of forming a hemostatic product. A porous base is prepared that is capable of substantially dissolving when applied to a bleeding wound. A hemostatic agent is mixed with at least one salt to prepare a hemostatic mixture. The hemostatic mixture is dispersed on the porous base to form the hemostatic product.

Abstract: A method of causing delayed hemostasis. A hemostatic product is formed by applying a hemostatic agent to a dextran support. The hemostatic agent is provided with at least one of a reduced concentration and a reduce availability. The hemostatic product is applied to a wound from which blood is being discharged. At least one foreign object or pathogen is proximate the wound. Hemostasis is progressively caused so that blood continues to be discharged from the wound to cause the at least one foreign object or pathogen to move away from the wound.

Abstract: A method of inducing hemostasis in a wound. A hemostatic product is applied to a wound. The hemostatic product includes at least one hemostasis component. The hemostatic product is retained with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product. At least a portion of the hemostatic product is dissolved. Hemostasis is induced in the wound with the at least one hemostasis component. The hydrogel material is separated from the wound. Substantially all of the hemostatic product remains on the wound.

Abstract: Various systems, processes, tools and techniques are provided for managing and processing alerts associated with different business events that impact a corporate entity. In various aspects, the system may employ an event-driven architecture to process business events and then provide customers and other system users with a mechanism for having have visibility into those business events through a subscription process, for example. Subscribers may be offered the ability to tap into different streams of business events, filter the event streams to obtain information only for events of interest, and then receive alerts associated with the events via one or more communication media or channels.